NCT07062380Recruiting
AI-Based Prediction of HCC Recurrence Patterns After Resection (APAR)
Prospective Validation of Multimodal Deep Learning Models for Predicting Recurrence Patterns in Early-Stage Hepatocellular Carcinoma After Resection: A Natural Treatment Cohort Stratification Study
Source: ClinicalTrials.gov · Last updated 3 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This observational study aims to validate a deep learning model for predicting aggressive recurrence patterns in patients with early-stage liver cancer (HCC) after surgery. The main question it aims to answer is: Can the AI model accurately identify patients at high risk of cancer recurrence within 2 years after surgery? Participants will provide clinical data and undergo standard surgery, followed by 2-year imaging surveillance. Their data will be used for both AI prediction and validation of recurrence patterns.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 353 (estimated)
- First submitted
- 2 Jul 2025
- Start date
- 10 Jun 2025
- Primary completion date
- 10 Jun 2026
- Lead sponsor
- Tongji Hospital
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07062380
What you commit to
- Study type: Observational
- Planned participants: 353
- From 10 Jun 2025 to the primary completion date, 10 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent other malignancies (except cured non-melanoma skin cancer or cervical carcinoma in situ).
Other illness
- History of organ transplantation.
Other
- Postoperative pathology confirms non-HCC diagnosis.
- Pregnant or lactating women.
- Inability to comply with the study protocol or follow-up schedule.
Who the study is looking for
- Aged 18-75 years, regardless of gender.
- BCLC stage 0-A, scheduled for curative liver resection.
- Preoperative clinical diagnosis of hepatocellular carcinoma (HCC).
- Availability of dynamic contrast-enhanced MRI within 1 month before surgery, with acceptable image quality.
- Child-Pugh liver function score ≤7.
- ECOG Performance Status (PS) 0-1.
- No severe organic diseases of the heart, lungs, brain, or other vital organs.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tongji Hospital Coordinator of this site? Confirm its status | Wuhan | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.